Website intended for a NZ health professional readership
This month sees a change to the targeted diseases of the Newborn Metabolic Screening Programme; here we review the new programme, its history, how it operates and how GPs can best make use of it
1. Albert B, Heather N, Derraik J et al. Neurodevelopmental and body composition outcomes in children with congenital hypothyroidism treated with high-dose initial replacement and close monitoring. J Clin Endocrinol Metab 2013;98:3663–70.
2. Knox W. An evaluation of the treatment of phenylketonuria with diets low in phenylalanine. Pediatrics 1960;26(1).
3. Wilcken B, Haas M, Joy P et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 2007;369:37–42.
4. Kwan A, Abraham R, Currier R et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 2014;312(7):729–38.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
